BRIEF—Ono files in Japan for ONO-7643 approval

Ono Pharmaceutical has filed for Japanese approval of ONO-7643, anamorelin hydrochloride, a candidate for improvement of body weight loss and anorexia in patients with cancer cachexia.

Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight and anorexia associated with cancer. To date, an effective treatment method for the condition has not been established.

Developed by Helsinn Healthcare, Ono has exclusive rights to develop and commercialize the product in Japan, South Korea and Taiwan.